Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone therapy increases carotid intima-media thickness and plaque score with von Willebrand factor activity elevation in patients with malignant lymphoma-Reference-Cited by-同舟云学术

Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone therapy increases carotid intima-media thickness and plaque score with von Willebrand factor activity elevation in patients with malignant lymphoma

Published:2021-10-18 Issue: Volume: Page:1-6
ISSN:1120-009X
Container-title:Journal of Chemotherapy
language:en
Short-container-title:Journal of Chemotherapy

Author:

Shimizu Naomi¹,Ngayama Daiji²,Watanabe Yasuhiro²,Yamaguchi Takashi²,Nakamura Shoko²,Ohira Masahiro²,Saiki Atsuhito²,Onda Hiroki²,Yamaoka Shuhei²,Abe Kazuki²,Nakaseko Chiaki³,Tatsuno Ichiro²

Affiliation:

1. Department of Hematology, Toho University Medical Center Sakura Hospital, Chiba, Japan

2. Center for Diabetes, Metabolism and Endocrinology, Toho University Medical Center Sakura Hospital, Chiba, Japan

3. Department of Hematology, International University of Health and Welfare School of Medicine, Chiba, Japan

Publisher

Informa UK Limited

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/1120009X.2021.1988202

Reference16 articles.

1. New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta‐2 microglobulin in patients with diffuse large B‐cell lymphoma treated with R‐CHOP: Spanish Lymphoma Group Experience (GELTAMO)

2. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial

3. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

4. Impact of platinum-based chemotherapy on the progression of atherosclerosis

5. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy decreases lean body mass and appendicular skeletal muscle mass index even until one year after the final treatment in patients with B-cell non-Hodgkin lymphoma;Journal of Chemotherapy;2024-07-11

2. The chemotherapeutic drug doxorubicin does not exacerbate p16Ink4a-positive senescent cell accumulation and cardiometabolic disease development in young adult female LDLR-deficient mice;Toxicology and Applied Pharmacology;2023-06

3. Coronary atherosclerosis and chemotherapy: From bench to bedside;Frontiers in Cardiovascular Medicine;2023-01-19